WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics, today announced that investors, journalists and
the general public are invited to listen to a live webcast of the
Company's analyst and investor community meeting on April 12, 2013. The
webcast will begin at 8:30 a.m. ET and may be accessed through the
Investor Information section of the Company's website, www.immunogen.com.
The meeting is expected to last approximately three hours, including a
short break, and to contain updated information related to the status of
the Company's IMGN901 NORTH Phase II trial and its IMGN853 abstract
submitted to ASCO. An archive of the webcast will be available on the
Company's website through April 26, 2013.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
Targeted Antibody Payload (TAP) technology uses a tumor-targeting
monoclonal antibody to deliver one of ImmunoGen's highly potent
cancer-cell killing agents specifically to tumor cells. Ten TAP
compounds are now in the clinic, of which three are wholly owned by the
Company. The most advanced compound using ImmunoGen's TAP technology,
KADCYLA (formerly T-DM1), has been approved for marketing in the US and
is undergoing regulatory review in Europe and Japan; it is being
commercialized in the US by Genentech, a member of the Roche Group. More
information about ImmunoGen can be found at www.immunogen.com.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media